Abaxis (ABAX) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq touch new peaks as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Nasdaq notches record high close as investors focus on earnings
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2017
October 25, 2016 4:01 PM EDTUNION CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the second fiscal quarter ended September 30, 2016.
Second quarter overview:
Revenues of $58.6 million, up 5% over last year's comparable quarter. Diluted net income per share from continuing operations of $0.51, compared to $0.34 from last year, up 50%. Diluted net income per share for the second quarter includes the effect of the gain from... More


